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Background. Human immunodeficiency virus–associated
nephropathy (HIVAN) has become the third leading cause of
end-stage renal disease (ESRD) in African Americans, and
is expected to grow exponentially. Highly active antiretrovi-
ral therapy (HAART) has significantly prolonged the survival
of patients with HIV infection. Despite the growing number of
HIV-positive dialysis patients with prolonged life expectancy,
kidney transplantation with immunosuppression has been de-
clined because it is considered a waste of scarce donor kidneys
due to potential increases in morbidity and mortality.
Methods. The institutional review board of Drexel Univer-
sity College of Medicine and Hahnemann University Hospi-
tal approved this prospective study. The aim was to find out
safety and success of kidney transplantation, and the effect of
immunosuppression on HIV infection. Forty HIV-positive dial-
ysis patients received kidney transplantation between February
2001 and January 2004. Patient inclusion criteria were mainte-
nance of HAART, plasma HIV-1 RNA of <400 copies/mL, ab-
solute CD4 counts of 200 cells/lL or more. Immunosuppression
was basiliximab induction and maintenance with cyclosporine,
sirolimus, and steroids. HAART was continued post-transplant.
Acute rejections were diagnosed by biopsy and treated with
methylprednisolone. Surveillance biopsies were completed at
1, 6, 12, and 24 months, and evaluated for subclinical acute re-
jection, chronic allograft nephropathy, and HIVAN.
Results. One- and 2-year actuarial patient survival was 85%
and 82%, respectively, and graft survival was 75% and 71%,
respectively. Plasma HIV-1 RNA remained undetectable, and
CD4 counts remained in excess of 400 cells per lL with no
evidence of AIDS for up to 2 years.
Conclusion. One- and 2-year graft survival is comparable to
other high-risk populations receiving kidney transplantation.
One- and 2-year patient survival is higher than HIV patients
maintained on dialysis. Immunosuppression does not adversely
affect HIV recipients maintained on HAART in the short term.
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Before the highly active antiretroviral therapy
(HAART) era, HIV was one of the top 10 causes of death
among adults younger than 44 years old [1]. HAART
has significantly reduced the mortality, and prolonged
the life expectancy of HIV-positive patients, and 5%
to 10% of HAART-maintained patients develop HIV-
associated nephropathy (HIVAN) and end-stage renal
disease (ESRD). HIVAN has become the third leading
cause of ESRD among young African Americans in the
United States [2, 3]. Until recently, chronic dialysis was
the only form of treatment available for these patients.
Kidney transplantation was not considered an option for
fear of increased morbidity and mortality due to ther-
apeutic immunosuppression. The allocation of cadaver
kidneys to these patients was also considered improper
due to expected inferior patient graft survival [4, 5]. This
study was initiated to determine the safety and success
of kidney transplantation as an alternative to dialysis and
to improve the quality of life in HIV-positive ESRD pa-
tients, and to evaluate the effect of chronic immunosup-
pression on the HIV status.
METHODS
Patient selection and institutional approval
The institutional review board of Drexel University
College of Medicine and Hahnemann University Hospi-
tal (Tenet facility) approved a protocol for kidney trans-
plantation in HIV-positive dialysis patients in February
2001. Forty HIV patients with ESRD were transplanted
between February 2001 and January 2004. The first 10
patients were transplanted under the IRB-approved pro-
tocol, and the remaining 30 patients were transplanted
as standard of care following the same protocol. Selec-
tion criteria required that patients be adherent to dialysis
treatment and HAART, have plasma HIV-1 RNA <400
copies/mL, and absolute CD4 count of ≥200 cells/lL
of blood, were able to sign informed consent, and rec-
ommended by their treating nephrologists, dialysis so-
cial worker, and infectious disease specialist. All patients
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were evaluated according to standard pretransplant cri-
teria [6, 7]. This study was entirely funded by the clinical
revenue of the authors from the transplant program, and
no external funding was obtained.
Immunosuppression protocols
Immunosuppression consisted of basiliximab induc-
tion and maintenance cyclosporine, sirolimus, and pred-
nisone. Basiliximab, 20mg, was infused on the day of
transplant and on postoperative day 4. Cyclosporine,
modified, and sirolimus were initiated orally on day 1.
Cyclosporine doses were adjusted to obtain trough blood
levels of 150 to 200 ng/mL of whole blood. Sirolimus
doses were adjusted to a goal trough level of 5 to 10 ng/
mL. Cyclosporine and sirolimus levels were measured
by monoclonal antibody method and high-performance
liquid chromatography-mass spectrometry (HPLC-MS)
method, respectively [8, 9]. Steroids were given as
250 mg of intravenous methylprednisolone on the day
of transplantation, 125 mg on day 1, and converted to
30 mg of oral prednisone tapered by 5 mg weekly and
maintained at 5 mg/day.
Surveillance biopsy
All recipients underwent surveillance biopsies at 1, 6,
12, and 24 months after transplantation. Renal tissue was
stained with hematoxylin and eosin, trichrome, and Jones
silver stain. Biopsies were scored for acute and chronic
allograft nephropathy according to Banff 1997 criteria
[10]. Biopsies were assessed for HIVAN, infection, and
recurrent/de novo disease [11]. Subclinical acute rejec-
tion (SCAR) was defined as clinically stable kidney func-
tion with pathologic signs of acute rejection in proto-
col biopsy [abstract; Kumar MSA et al, Transplantation
74:487, 2002].
Diagnosis and treatment of acute rejection and
subclinical acute rejection
Acute rejection was diagnosed by persistent elevation
of serum creatinine by 15% or more above baseline and
confirmed by biopsy. Acute and subclinical rejections
were treated with intravenous methylprednisolone, 250
mg daily for 3 days. Lymphocyte depleting antibodies
were not used for treatment of rejection. Steroid-resistant
antibody-mediated rejections were treated with intra-
venous immune globulin and/or 1 dose of 375 mg/m2 of
rituximab.
Infection prophylaxis
Infection prophylaxis was ganciclovir or valgancyclovir
for cytomegalovirus, trimethoprim/sulfamethoxazole or
dapsone for Pneumocystis carinii, and nystatin for oral
and esophageal thrush for 200 days after transplantation.
Table 1. Recipient and donor characteristics
Recipient and donor characteristics Number of patients
Number of recipients 40
Male gender 37
African American race 39
Mean age ± SD 46 ± 6
Mean body mass index 25.4 ± 2.2
Pretransplant diabetes mellitus 2
Cause of end-stage renal disease
Hypertension 18
HIVAN 10
HIVAN and hypertension 3
Unknown cause 3
Type 1 diabetes mellitus 1
Adult polycystic kidney disease 1
Mesangioproliferative glomerulonephritis 1
Donor source
Cadaver donor 36
Living donor 4
Cadaver donor characteristics
History of drug abuse 8
Alternative lifestyle 3
Expanded criteria donors 8
Common cadaver donor pool 17
Post-transplant monitoring and HAART therapy
A multidisciplinary transplant team performed out-
patient surveillance. Post-transplant monitoring included
serial measurements of serum creatinine, calculated crea-
tinine clearance, liver function tests, and complete blood
counts every month. Urine was tested for proteinuria and
infection every 2 months. All patients continued their
HAART regimens. Post-transplant monitoring of HIV
status included monthly measurement of plasma HIV-1
RNA copies and absolute CD4 lymphocyte count. Persis-
tent increases in viral copies were investigated for HIV
drug resistance, and treated by a change in the HAART
regimen [12].
Statistical methods
Computerized SPSS system (Chicago, IL, USA) was
used for statistical analysis, and actuarial patient and graft
survival by Kaplan-Meier estimate.
RESULTS
Between February 2001 and January 2004 40 HIV-
positive dialysis patients received kidney transplants. Re-
cipient and donor characteristics are listed in Table 1.
Patient and graft survival
All recipients completed 6 months after transplanta-
tion; 35 (87%) patients completed 12 months, and 15
patients (37%) 24 months or more post-transplantation.
The median and mean follow-up was 19.2 months and
20.4 months, respectively. One- and 2-year actuarial pa-
tient survival was 85% and 82%, respectively, and graft
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Table 2. Cause of patient death
Post-transplant Number of
Cause of death day patients
Pulmonary embolism 2 1
Anaphylactic reaction to drug 6 1
Intractable gastrointestinal bleeding 107 1
Sepsis
Chest infection 37 1
Necrotizing fasciitis 238 1
Infection of the lymphocele 285 1
Myocardial infarction 545 1
Table 3. Cause of graft loss
Days of Number of
Cause of graft loss graft loss grafts lost
Patient deaths from Table 2 2, 6, 37, 107, 238, 7
285 and 545
Acute vascular rejection 12 1
Bleeding at the transplant site 15 1
Hemolytic uremic syndrome 55 1
Steven Johnson syndrome due 152 1
to Dapsone
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Fig. 1. Two-year actuarial patient and graft survival.
survival was 75% and 71%, respectively. Seven patients
died between 2 days and 18 months after transplantation.
The causes of death and graft loss are shown in Tables 2
and 3, respectively.
Renal function
The mean serum creatinine at 1 year and 2 years was
2.0 and 2.2 mg/dL, respectively, and calculated creatinine
clearance was 55 and 40 mL/min, respectively (Fig. 1).
Acute rejection
Acute rejection was diagnosed in 9 (22%) recipients
and treated with methylprednisolone; 2 with combined
cell- and antibody-mediated rejection also received intra-
venous immune globulin and rituximab. Acute rejection
was reversed or controlled in 8 recipients, and 1 required
transplant nephrectomy for irreversible vascular rejec-
tion. Three recipients developed acute rejections due to
subtherapeutic levels of cyclosporine caused by drug in-
teractions with HAART therapy, and 2 due to noncom-
pliance.
Results of protocol biopsies
Protocol biopsies were completed as per protocol.
SCAR was diagnosed in 10 (29%) patients. SCAR was
treated with pulse doses of intravenous methylpred-
nisolone. In 6- to 24-month protocol biopsies, chronic
allograft nephropathy was mild in 11, moderate in 15,
severe in 2, and absent in 6. Two patients expired be-
fore the 6-month biopsy period. HIVAN was diagnosed
in 3 patients in 12-month protocol biopsies. Two patients
have proteinuria of more than 1500 mg/day, and 1 pa-
tient remains asymptomatic. The diagnosis of HIVAN
was based on collapsing glomerulonephritis and other
characteristics described previously [13, 14]. The simi-
larity of pathologic features between transplant kidney
biopsy and native kidney pathology in these patients was
also considered in making a diagnosis of HIVAN in trans-
plant kidney. Acute cyclosporine nephrotoxicity was seen
in 7 recipient biopsies and was treated by dose reduction.
Post-transplant complications
Six patients remained free of complications without
hospitalization. Table 2 shows complications, their treat-
ment, and outcome.
HIV status in the post-transplant period
Plasma HIV-1 RNA remains undetectable in 30 recip-
ients. In 4 patients who returned to dialysis, HIV remains
under control with continuation of HAART. The remain-
ing 6 patients who expired had undetectable HIV-1 RNA
in the blood, and CD4 counts remained greater than
400 cells/lL of blood until the time of their death. Four
recipients developed acute pancreatitis, 2 due to didano-
sine therapy. These patients experienced temporary ele-
vation of plasma HIV-1 RNA for approximately 3 weeks
after temporary cessation of didanosine; after resump-
tion of modified HAART, plasma HIV-1 RNA promptly
returned to undetectable levels. Three recipients showed
elevation of plasma HIV-1 RNA from undetectable to a
range of 1570 to 70,000 copies/mL due to drug resistance
confirmed by resistance studies. HAART modifications
resulted in undetectable plasma HIV-1 RNA. Absolute
CD4 lymphocyte counts fluctuated, but in most recipients
trended upward. Figure 3 shows the mean CD4 counts at
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Table 4. Post-transplant complications
Number of
Complication patients Treatment Outcome
Surgical complications
Urine leak
2 Surgical correction Resolved
Hematoma 2 Surgical drainage Resolved
Lymphocele 3 Percutaneous drainage by intervention
radiology in 2 and open surgical
drainage in 1
Death due to sepsis in recipients with
percutaneous drainage (2); lymphocele
resolved in 1
Gastrointestinal bleeding 1 Blood transfusion Death
Bleeding at transplant site 1 Transplant nephrectomy Graft loss
Nonsurgical complications
Pulmonary embolism 1 Anticoagulation Death
Congestive heart failure 2 Medical management Resolved
Insulin dependent diabetes mellitus 6 Insulin therapy Controlled
Anaphylactic reaction to IVIG therapy 1 Supportive treatment Death due to respiratory failure
Infectious complications
Wound infection 1 Antibiotic therapy Resolved
Chest infection due to Pseudomonas
aeroginosa in 1 and Staphylococcus
aureus in 1
2 Diagnosis by bronchioalveolar lavage
and lung biopsyAntibiotic therapy
Resolved (1); death (1)
Sepsis 3 Antibiotic therapy Resolved
Urinary tract infection 12a Antibiotic therapy Resolved
HAART-related complications
Acute pancreatitis 4 Temporary withdrawal and change of
HAART regimen
Resolved
HIV drug resistance 3 Phenotype study and change in HAART
regimen
Controlled
Immunologic complications
Acute rejection 9 Steroid therapy Controlled (8); graft loss (1)
Hemolytic uremic syndrome 2 Discontinuation of cyclosporine Graft loss (2)
Drug allergy 1 Discontinuation of dapsone Graft loss
aNine admissions due to urinary tract infection.
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Fig. 2. Mean serum creatinine levels and cre-
atinine clearances for 2 years’ post-transplant.
monthly intervals. Opportunistic infections were not ob-
served in these 40 recipients.
HAART and immunosuppressive regimens
All recipients continued HAART combined with im-
munosuppression. The majority of recipients received
protease inhibitor (PI) or non-nucleoside reverse tran-
scriptase inhibitor (NNRTI)-based regimens. Immuno-
suppression for all patients consisted of basiliximab,
cyclosporine, sirolimus, and prednisone. Due to the
drug interaction profile of the various HAART regi-
mens with immunosuppression, the daily requirement
of cyclosporine and sirolimus varied dramatically among
recipients. Recipients receiving PI-based HAART reg-
imens required much lower cyclosporine and sirolimus
doses than convention dictates, with many requiring once
daily to once weekly dosing to maintain target trough
levels. The mean daily cyclosporine dose in these re-
cipients was 65 ± 40 mg/day. In comparison, the mean
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counts in the peripheral blood.
daily cyclosporine dose in recipients using NNRTI-based
regimens was 313 ± 208 mg/day, and 186 ± 78 mg/day
for those taking only nucleoside reverse transcriptase
inhibitors (NRTI). Similarly, the mean daily dose of
sirolimus ranged from 0.1 mg to 1.0 mg with dosing as
little as once a week. Figure 3 shows mean cyclosporine
dose and levels.
DISCUSSION
This study was carried out in HIV-positive patients with
ESRD who were stable and compliant with HAART and
dialysis. HIV patients on dialysis who were not compli-
ant and had higher plasma HIV-1 copies in blood were
excluded from the study. The introduction of HAART
for the treatment of HIV infection has significantly de-
creased the mortality, and extended the life span of
HIV-positive patients. Increased life span has resulted
in these patients developing long-term complications of
HIV infection, including ESRD. HIV patients may de-
velop ESRD secondary to preexisting conditions such
as diabetes and hypertension, or the primary cause may
be HIVAN [10, 15]. HIVAN is seen more frequently in
male African American patients with a history of in-
travenous drug abuse, and progresses rapidly to ESRD,
requiring renal replacement therapy [16, 17]. HIVAN
may be treated by steroid therapy with a low success
rate that postpones the inevitable ESRD by only a few
months. Chronic dialysis treatment was the only option
available for these patients until 2001. HIV infection was
considered a contraindication for kidney transplantation
because of the expected increased in morbidity and mor-
tality from surgery and immunosuppression based on pre-
HAART experience [5]. Expected inferior survival led
many to believe it morally and ethically inappropriate
to allocate kidneys to these patients for fear of wasting
scarce resources [4, 5, 18]. A survey conducted by our
program showed that in the Philadelphia region, 2% to
5% of dialysis patients were HIV-positive and were main-
tained on HAART (unpublished data). Further analysis
of our survey showed that many of these patients were
intolerant to dialysis, and were seeking kidney transplan-
tation, but were denied the opportunity by all transplant
programs in Philadelphia. Many of these young HIV-
positive patients compliant with HAART and dialysis
treatment were referred to Hahnemann University Hos-
pital transplant program for kidney transplantation in
1999 and 2000. These patients had improved their lifestyle
by strict adherence to recommended medical treatment
and modifying their personal and social behaviors. We
initiated an IRB-approved protocol for kidney transplan-
tation in HIV-positive patients in February 2001 to offer
these patients an alternative treatment to chronic dialy-
sis therapy, and to improve their quality of life. Patient
selection criteria were rigorous to protect their inter-
ests, and to minimize the potential aggravation of HIV
disease.
Earlier reports of transplantation in HIV patients are
sporadic and include smaller series of patients, and the
follow-up was 1 year or less [19, 20, abstract; Kumar MSA
et al, Am J Transplant 2 (Suppl 3):174, 2002]. In this series,
39 patients were African American and 1 was Caucasian.
Male gender was predominant (91%). This represents the
prevalence of HIV disease in metropolitan areas of the
United States of America. Before transplantation, all pa-
tients were compliant with medical treatment, and their
HIV infection was controlled, as shown by their plasma
HIV-1 RNA copies and CD4 counts. Our results demon-
strate that HIV-positive patients maintained on HAART
are capable of mounting an immune response, as evi-
denced by a rejection rate of 25%. This indicates that allo-
graft reactivity is preserved in these patients, and without
immunosuppression they will reject an allograft. There
are no data available regarding the long-term effects of
combining immunosuppression and HAART. Our data
extend up to 2 years and show that the combination of
HAART and low-dose immunosuppression utilized is not
associated with serious adverse effects. For these reasons,
we continue to utilize low doses of immunosuppression
with HAART. This could explain higher rates of acute re-
jections in these patients compared to non-HIV patients.
Graft function, as measured by serum creatinine, re-
mains around 2 mg/dL in most of these patients. This
may be explained by the use of marginal kidneys, the
synergistic nephrotoxicity of cyclosporine and sirolimus,
and drug interactions with HAART [21]. In the Philadel-
phia region, 30% of cadaver kidneys are harvested from
marginal donors according to UNOS criteria [22]. Kidney
biopsies in recipients with higher serum creatinines did
not show any structural changes to explain poor function.
In these patients, reduction of cyclosporine and sirolimus
improved the kidney function, indicating that this com-
bination of HAART and immunosuppression may be
nephrotoxic. HAART doses were not reduced for fear
of increased viremia.
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Fig. 4. Mean sirolimus doses and trough
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Six recipients (15%) died within 1 year, and 1 in the
second year. The causes of death were unrelated to HIV
infection in 4 patients (1 each due to pulmonary em-
bolism, myocardial infarction, anaphylactic reaction, and
post surgical bleeding). The remaining 3 patients died of
bacterial infection, which could be the result of added
immunosuppression with HIV-positive status. Infection
of lymphocele and severe sepsis occurred in 2 recipients
with percutaneus drainage. Since the death of 2 recipients
with overwhelming infections, our policy is to surgically
drain the lymphoceles in HIV patients. We believe that
at least 2 recipients with chest infection died because of
delay in seeking treatment for 48 hours or longer. Most
of these deaths occurred in the first 15 patients, and since
that time frequent outpatient surveillance and intense pa-
tient education to seek early treatment has decreased the
death rate. The plasma HIV-1 RNA copies in all patients
at the time of death remained undetectable, and CD4
counts were greater than 400.
One- and 2-year patient survival in our transplant se-
ries was 85% and 82%, respectively, compared to the re-
ported 58% and 41% survival of HIV patients on dialysis
[23]. The United States Renal Data System reported a
1-year death rate of 32.7% in HIV patients maintained
on dialysis [22].
In this series, 97% were African American, and 50%
received marginal kidneys; both characteristics are inde-
pendent risk factors for lower graft survival [24]. Non-
HIV African American kidney recipients have 1- and 2-
year graft survival of 85% and 78%, respectively [24, 25].
The graft survival in this series of HIV-positive transplant
recipients is comparable to the UNOS data on non-HIV
African American recipients.
The immunosuppressive agents selected for this pro-
tocol were chosen to minimize the aggravation of HIV
infection and the potential side effects of combin-
ing HAART and immunosuppression. Basiliximab is a
nonlymphocyte-depleting induction agent with minimal
side effects [26]. Cyclosporine was chosen because it has
demonstrated some in vitro antiretroviral activity [27].
Sirolimus, an effective adjunct, is typically given once
a day, and was chosen to decrease the pill burden, and
to obtain compliance with the combined regimen with
fewer gastrointestinal side effects. Steroids have tradi-
tionally been integral to immunosuppression. Clinical
acute rejection in this series is higher than in non-HIV
patients, and this may be due to low levels of immuno-
suppression used to avoid infectious. Cytochrome P450-
3A4 drug interactions between HAART and immuno-
suppressives posed a challenge in dosing cyclosporine
and sirolimus. Earlier reports in liver recipients showed
that ritonavir is a very potent inhibitor of CYP450-3A4,
and interferes with tacrolimus metabolism [28]. In our
series, 9 patients received ritonavir-based HAART, and
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7 of these experienced acute cyclosporine nephrotoxic-
ity confirmed by biopsy despite low cyclosporine levels,
implying that ritonavir potentiates cyclosporine nephro-
toxicity regardless of trough level. In patients experi-
encing toxicity, doses were decreased with resolution of
side effects. Eleven patients treated with efavirenz, a
mixed inducer and inhibitor of CYP450-3A4, had sub-
therapeutic cyclosporine and sirolimus levels, and 3 of
these patients developed acute rejection [29]. One patient
treated with efavirenz was unable to achieve therapeutic
cyclosporine levels despite increased cyclosporine dose
and addition of a CYP450-3A4 inhibitor, ketoconazole;
this patient developed vascular rejection and required
transplant nephrectomy. Cyclosporine is known to affect
the blood levels of antiretroviral drugs metabolized via
the hepatic microenzyme systems [30]. Evaluation of an-
tiretroviral levels was not a part of this study, and further
investigation of these interactions is warranted.
The monitoring of combined immunosuppression and
HAART due to major drug interactions is challenging
and requires diligent surveillance and the coordinated
care of transplant professionals, pharmacists, and HIV
specialists. Further investigation to elucidate the com-
plicated drug interaction profile and combined toxicity
of imunosuppressives and HAART is a pressing need.
Longer-term studies of patient and graft outcomes, the
effect of prolonged immunosuppression on HIV therapy,
and the benefit to patients and society of transplantation
in HIV-positive patients are required. Although barri-
ers to transplantation in relatively healthy HIV-positive
patients remain, moral and ethical arguments have been
made to refute them [31]. This study provides medical ev-
idence that kidney transplantation in select HIV-positive
patients maintained on effective HAART is safe and
provides significantly higher 1- and 2-year patient sur-
vival compared to dialysis treatment in select group of
HIV patients. One- and 2-year actuarial graft survival in
HIV recipients is equivalent to other high-risk groups.
HAART remains effective in controlling HIV infection
over 2 years of follow-up after kidney transplantation
and immunosuppression with basiliximab induction and
low-dose 3-drug maintenance. None of the patients devel-
oped AIDS or opportunistic infections with the immuno-
suppression regimen used in our center. These patients
tolerated combined immunosuppression and HAART
medications. The economics of transplantation and dial-
ysis in HIV patients with ESRD need to be estimated
and applied to clinical practice. Based on our experiences
we conclude that positive HIV status should not be con-
sidered a contraindication for kidney transplantation in
select patients.
Reprint requests to Mysore S. Anil Kumar, MS417, Division of Trans-
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